Pet and Animal Brands Around the World Celebrate Their Win at the 2023 - 2024 World Branding Awards Animalis Edition in Vienna
27.7.2023 21:00:00 EEST | Business Wire | Press release
The third instalment of the Animalis Edition at the 2023 - 2024 World Branding Awards welcomed pet and animal brands from around the world, celebrating their achievements as National, Regional, and Global Winners.
Held at the prestigious Hofburg Palace in Vienna, the awards ceremony was hosted by Howard Nightingall and welcomed winners across various categories, such as pet food, retail, wellness, aquatic products, and more.
“The Animalis Edition of the Awards are an acknowledgement to the tireless effort of the teams that build and maintain their brand presence in an ever changing market. As winners, these brands have established strong brand recall, top-of-mind awareness, and trust among their consumers.” said Richard Rowles, Chairman of the World Branding Forum.
Over 100,000 consumers participated in a global online survey and nominated more than 1,500 brands. Of these, only 100 of the best brands from 30 countries were named as winners.
Buddy Brands, Coo & Riku, Dymax, FRONTLINE, Hikari, Kaniva, and Taiyo were amongst the brands announced as winners. To win the World Branding Awards is no easy accolade, and cements their position as the top in their industry.
National tier winners include Coo & Riku (Japan), DeliBest (Switzerland), Dogotel & Spa (Hong Kong), Dymax (Singapore), Global Pet Foods (Canada), Halti (United Kingdom), Happi Doggy (Singapore), Heads Up For Tails (India), Hikari (Japan), Kaniva (Thailand), Kelly & Co’s (Thailand), NurturePro (Singapore), Petio (Japan), PowerCat (Malaysia), Royal Veterinary College (United Kingdom), TopBreed (The Philippines), Truline (United Kingdom), and VanCat (Turkey).
Regional tier winners include Alps Natural (Hong Kong), EHEIM (Germany), Hydra (USA), JUWEL Aquarium (Germany), Kit Cat (Singapore), and Taiyo (India).
Global winners who proved excellence and impeccable branding in their industry include Buddy Brands (USA), FRONTLINE (France), KONG (United Kingdom), Tetra (USA), and FURminator (USA).
As the 2023 - 2024 World Branding Awards Animalis Edition draws to a close, the eagerly anticipated Global Edition of the World Branding Awards will return to the stage in November in Kensington Palace, London.
For more information, visit awards.brandingforum.org.
###
ABOUT WORLD BRANDING AWARDS
The World Branding Awards is the premier awards of the World Branding Forum, a registered non-profit organisation. The awards recognise the achievements of some of the world’s best brands.
SOCIAL MEDIA
Facebook: https://www.facebook.com/worldbrandingforum/
Twitter: https://twitter.com/WorldBranding
Instagram: https://www.instagram.com/worldbranding/
LinkedIn: https://linkedin.com/company/world-branding-forum
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230727718843/en/
Contact information
Email: editorial@brandingforum.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer31.8.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). At IA2, ZIIHERA plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared with trastuzumab plus chemotherapy, meeting the remaining primary endpoint analysis of the study. IA2 also provided longer follow-up data for the TEVIMBRA plus ZIIHERA and chemotherapy regimen, demonstrating an improved OS hazard ratio, continued durable outcomes, and a generally manageable safety profile. These results reinforce findings from IA1, in which the regimen met the progression-free survival (PFS) and OS endpoints, wi
GigaDevice Strengthens EMEA and Southeast Asia Market Reach Through Strategic Partnership with Rutronik31.8.2026 10:00:00 EEST | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced a new strategic franchise partnership with Rutronik Elektronische Bauelemente GmbH, one of Europe’s leading broadline distributors of electronic components. The agreement covers EMEA and Southeast Asia, including India, and provides customers with broader access to GigaDevice’s comprehensive portfolio of microcontrollers, sensors, and power management solutions. The partnership further strengthens GigaDevice’s distribution network and local market presence across key regions. With its strong presence across Europe and growing coverage in Southeast Asia, Rutronik provides GigaDevice with an established channel supported by extensive market reach, technical expertise, and customer relationships. The collaboration will help expand access to GigaDevice’s embedded solutions across a broad range of applications and industries, including indus
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 15:23:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. Additionally, the data expand the potential application of RNAi to uncontrolled hypertension, the world’s leading cause of cardiovascular disease. “With the power of our RNAi therapeutics platform, we have the potential to make a transformational impact on cardiovascular care,” said Pushkal Garg, M.D., Chief Research and Development Officer at Alnylam. “The data presented at ESC demonstrate the consistency of clinical outcomes achieved by RNAi-powered TTR silencing, reinforcing our conviction in AMVUTTRA as a first-line treatment option for ATTR-CM. With
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release
Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom